«Liperon» is a project company, developing an innovative drug for treating influenza. The new drug (codename – Camphecin) is the first Russian direct-acting antiviral drug against influenza viruses (an inhibitor of viral hemagglutinin). The drug demonstrates high efficacy in preventing and treating influenza, induced by epidemically relevant virus types (as potent as Tamiflu). The drug is patented in Russia. «Liperon» is a participant of Skolkovo Innovation Center. Preclinical trials are nearing completion with the support of Russian Ministry of Industry and Trade and Skolkovo Foundation. Clinical trials are planned in 2020.